Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease†
Version of Record online: 27 OCT 2010
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 53, Issue 1, pages 62–72, January 2011
How to Cite
Liaw, Y.-F., Sheen, I.-S., Lee, C.-M., Akarca, U. S., Papatheodoridis, G. V., Suet-Hing Wong, F., Chang, T.-T., Horban, A., Wang, C., Kwan, P., Buti, M., Prieto, M., Berg, T., Kitrinos, K., Peschell, K., Mondou, E., Frederick, D., Rousseau, F. and Schiff, E. R. (2011), Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology, 53: 62–72. doi: 10.1002/hep.23952
Potential conflict of interest: Nothing to report.
- Issue online: 12 JAN 2011
- Version of Record online: 27 OCT 2010
- Accepted manuscript online: 1 SEP 2010 06:41PM EST
- Manuscript Accepted: 19 AUG 2010
- Manuscript Received: 16 JUL 2010
Additional supporting information may be found in the online version of this article.
|HEP_23952_sm_suppfig-S1.tif||153K||Supporting Figure 1: Disposition of study patients through 48 weeks. Two patients in each treatment group died prior to Week 48 but within 30 days of the last study drug dose; all 6 patients are counted as early discontinuations on double-blind study drug.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.